Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Feoktistov

Interventional Pain Medicine Northfield, IL Medical Doctor

NPI 1003143801 CMS profile 136116

191 Waukegan Rd Ste 300, Northfield, IL 60093

Open in the dashboard

General payments

$922,143

1,462 records reported · program years 2019–2025

Research payments

$8,750

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$208,306 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Alexander Feoktistov of Northfield, IL is reported in the CMS Open Payments database as having received $922,143 across 1,462 general payments and $8,750 in research payments paid to them. Separately, studies naming them as principal investigator received $208,306 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $195,911 266
2024 General $87,356 175
2023 General $50,433 123
2022 General $122,071 170
2021 General $172,576 245
2021 Research $8,750 1
2020 General $175,508 236
2019 General $118,289 247

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Feoktistov
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Alexander Feoktistov were reported at $195,911. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Alexander Feoktistov Interventional Pain Medicine median Middle half National median
2019 $118,289 $684 $216–$2,079 $163
2020 $175,508 $382 $122–$1,109 $114
2021 $172,576 $552 $167–$1,554 $132
2022 $122,071 $605 $187–$1,924 $149
2023 $50,433 $671 $195–$1,915 $160
2024 $87,356 $684 $206–$1,837 $164
2025 $195,911 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $291,944 327 payments
  2. Lilly USA, LLC $200,265 278 payments
  3. Lundbeck LLC $95,924 143 payments
  4. Allergan Inc. $86,577 122 payments
  5. Amgen Inc. $68,867 95 payments
  6. Teva Pharmaceuticals USA, Inc. $53,354 87 payments
  7. Axsome Therapeutics, Inc. $29,675 35 payments
  8. H. Lundbeck A S $28,003 30 payments
  9. Impel Pharmaceuticals Inc. $27,476 30 payments
  10. Biohaven Pharmaceuticals, Inc. $12,335 21 payments
  11. Other $27,722 294 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $623,152 285 payments
  2. Honoraria $109,991 39 payments
  3. Consulting Fee $90,521 61 payments
  4. Travel and Lodging $71,033 205 payments
  5. Food and Beverage $24,691 864 payments
  6. Grant $2,544 2 payments
  7. Education $211 6 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $170,162 181 payments
  2. EMGALITY $120,963 151 payments
  3. QULIPTA $101,439 115 payments
  4. BOTOX $89,774 63 payments
  5. REYVOW $89,688 97 payments
  6. VYEPTI Neurology $81,477 125 payments
  7. AIMOVIG $74,948 106 payments
  8. VYEPTI Neurology $42,429 47 payments
  9. AJOVY $30,799 52 payments
  10. Symbravo $29,675 35 payments
  11. Other $129,000 550 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $8,750 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

167

Median for Internal Medicine: 777

Drug cost

$118,414

Median for Internal Medicine: $73,373

Branded share of claims

60.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 29 $44,117
Nurtec Odt Rimegepant Sulfate Brand 25 $27,943
Aimovig Autoinjector Erenumab-Aooe Brand 21 $15,796
Botox Onabotulinumtoxina Brand 12 $15,476
Emgality Pen Galcanezumab-Gnlm Brand 14 $14,458
Gabapentin Generic 22 $264
Verapamil Hcl Generic 12 $142
Baclofen Generic 21 $141
Propranolol Hcl Generic 11 $77

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$143,801

Of which drugs: $94,121

Medicare patients

82

Average age 69

Services billed

20,363

60 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 72%
High blood pressure 60%
Depression 39%
Osteoporosis 21%
Ischemic heart disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 33 19,866 $94,121

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
$31,913 — —
QULIPTA
$23,475 — —
UBRELVY
$18,480 29 —
BOTOX
$11,219 12 19,866
ZEMBRACE SYMTOUCH
$631 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

1,463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record